Table 2.
Impact of combined SGLT2 inhibitors and GLP-1 receptor agonists on the 1-year percent change in the geometric mean of UACR in esaxerenone Group A and control Group B
| Presence or absence of concomitant medication | Cases | 1-year percent change in the geometric mean of UACR (%) | Independent t-test | |
|---|---|---|---|---|
| Group A | Total | 184 | − 19.3 ± 75.4 | |
| SGLT2 inhibitor (−) | 45 | − 20.7 ± 52.1 | P = 0.888 | |
| SGLT2 inhibitor ( +) | 139 | − 18.8 ± 81.6 | ||
| GLP-1 receptor agonist (−) | 145 | − 20.0 ± 80.0 | P = 0.810 | |
| GLP-1 receptor agonist ( +) | 39 | − 16.7 ± 55.63 | ||
| Group B | Total | 145 | 43.3 ± 160.4 | |
| SGLT2 inhibitor (−) | 103 | 56.3 ± 183.3 | P = 0.126 | |
| SGLT2 inhibitor ( +) | 42 | 13.3 ± 72.5 | ||
| GLP-1 receptor agonist (−) | 132 | 46.2 ± 166.1 | P = 0.485 | |
| GLP-1 receptor agonist ( +) | 13 | 13.5 ± 79.5 |
Mean ± SD, UACR urinary albumin-creatinine ratio, SGLT2 sodium-glucose co-transporter-2, GLP-1 glucagon-like peptide-1